Preferential accumulation of the near infrared heptamethine dye IR-780 in the mitochondria of drug-resistant lung cancer cells

Biomaterials

Volumn 35, Issue 13, 2014, Pages 4116-4124

  Wang, Yang ^a   Liu, Tao ^a   Zhang, Erlong ^a   Luo, Shenglin ^a   Tan, Xu ^a   Shi, Chunmeng ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Drug resistant cancer cells; IR 780 dye; Near infrared imaging; Theranostic agents; Tumor targeting

Indexed keywords

CANCER CELLS; HUMAN LUNG CANCER CELLS; LEWIS LUNG CARCINOMATA; MITOCHONDRIAL FUNCTION; MULTIFUNCTIONAL AGENTS; NEAR-INFRARED IMAGING; THERANOSTIC AGENTS; TUMOR TARGETING;

BIOLOGICAL ORGANS; CELL DEATH; DISEASES; INFRARED IMAGING; MITOCHONDRIA; TUMORS;

INFRARED DEVICES;

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; INDOCYANINE GREEN; IR 780; UNCLASSIFIED DRUG; 2-(2-(2-CHLORO-3-((1,3-DIHYDRO-3,3-DIMETHYL-1-PROPYL-2H-INDOL-2-YLIDENE)ETHYLIDENE)-1-CYCLOHEXEN-1-YL)ETHENYL)-3,3-DIMETHYL-1-PROPYLINDOLIUM; INDOLE DERIVATIVE;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CANCER SIZE; CARCINOGENICITY; CELL GROWTH; CELL MEMBRANE DEPOLARIZATION; CELL MIGRATION; CELL RENEWAL; CELL SURVIVAL; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL PERMEABILITY; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR RECURRENCE; ANIMAL; C57BL MOUSE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; LUNG NEOPLASMS; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; INDOLES; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MITOCHONDRIA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84896699809     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.01.061     Document Type: Article

References (37)

1. Duffy M.J. The war on cancer: are we winning?. Tumour Biol 2013, 34:1275-1284.
2. Steeg P.S. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006, 12:895-904.
3. Magee J.A., Piskounova E., Morrison S.J. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012, 21:283-296.
4. Valent P., Bonnet D., De Maria R., Lapidot T., Copland M., Melo J.V., et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer 2012, 12:767-775.
5. Zhou B.B., Zhang H., Damelin M., Geles K.G., Grindley J.C., Dirks P.B. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009, 8:806-823.
6. Lacerda L., Pusztai L., Woodward W.A. The role of tumor initiating cells in drug resistance of breast cancer: implications for future therapeutic approaches. Drug Resist Updat 2010, 13:99-108.
7. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med 2011, 17:313-319.
8. Matsumura Y., Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci 2009, 100:572-579.
9. Takebe N., Harris P.J., Warren R.Q., Ivy S.P. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011, 8:97-106.
10. Luo S., Zhang E., Su Y., Cheng T., Shi C. Areview of NIR dyes in cancer targeting and imaging. Biomaterials 2011, 32:7127-7138.
11. Zhang C., Liu T., Su Y., Luo S., Zhu Y., Tan X., et al. Anear-infrared fluorescent heptamethine indocyanine dye with preferential tumor accumulation for invivo imaging. Biomaterials 2010, 31:6612-6617.
12. Pham W., Medarova Z., Moore A. Synthesis and application of a water-soluble near-infrared dye for cancer detection using optical imaging. Bioconjug Chem 2005, 16:735-740.
13. Koya K., Li Y., Wang H., Ukai T., Tatsuta N., Kawakami M., et al. MKT-077, a novel rhodacyanine dye in clinical trials, exhibits anticarcinoma activity in preclinical studies based on selective mitochondrial accumulation. Cancer Res 1996, 56:538-543.
14. Lampidis T.J., Bernal S.D., Summerhayes I.C., Chen L.B. Selective toxicity of rhodamine 123 in carcinoma cells invitro. Cancer Res 1983, 43:716-720.
15. Zhou Z.H., Ping Y.F., Yu S.C., Yi L., Yao X.H., Chen J.H., et al. Anovel approach to the identification and enrichment of cancer stem cells from a cultured human glioma cell line. Cancer Lett 2009, 281:92-99.
16. Yu S.C., Ping Y.F., Yi L., Zhou Z.H., Chen J.H., Yao X.H., et al. Isolation and characterization of cancer stem cells from a human glioblastoma cell line U87. Cancer Lett 2008, 265:124-134.
17. Fan X., Liu S., Su F., Pan Q., Lin T. Effective enrichment of prostate cancer stem cells from spheres in a suspension culture system. Urol Oncol 2012, 30:314-318.
18. Tomshine J.C., Severson S.R., Wigle D.A., Sun Z., Beleford D.A., Shridhar V., et al. Cell proliferation and epidermal growth factor signaling in non-small cell lung adenocarcinoma cell lines are dependent on Rin1. JBiol Chem 2009, 284:26331-26339.
19. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003, 100:3983-3988.
20. Hirsch H.A., Iliopoulos D., Tsichlis P.N., Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009, 69:7507-7511.
21. Zhang L., Yao H.J., Yu Y., Zhang Y., Li R.J., Ju R.J., et al. Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells. Biomaterials 2012, 33:565-582.
22. Lagadinou E.D., Sach A., Callahan K., Rossi R.M., Neering S.J., Minhajuddin M., et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 2013, 12:329-341.
23. Ozdemir V., Williams-Jones B., Glatt S.J., Tsuang M.T., Lohr J.B., Reist C. Shifting emphasis from pharmacogenomics to theragnostics. Nat Biotechnol 2006, 24:942-946.
24. Pene F., Courtine E., Cariou A., Mira J.P. Toward theragnostics. Am J Respir Crit Care Med 2009, 37:S50-S58.
25. Weyers A., Yang B., Yoon D.S., Park J.H., Zhang F., Lee K.B., et al. Astructural analysis of glycosaminoglycans from lethal and nonlethal breast cancer tissues: toward a novel class of theragnostics for personalized medicine in oncology?. OMICS 2012, 16:79-89.
26. Bardhan R., Lal S., Joshi A., Halas N.J. Theranostic nanoshells: from probe design to imaging and treatment of cancer. Acc Chem Res 2011, 44:936-946.
27. Kunjachan S., Jayapaul J., Mertens M.E., Storm G., Kiessling F., Lammers T. Theranostic systems and strategies for monitoring nanomedicine-mediated drug targeting. Curr Pharm Biotechnol 2012, 13:609-622.
28. Pan D. Theranostic nanomedicine with functional nanoarchitecture. Mol Pharmacol 2013, 10:781-782.
29. Sumer B., Gao J. Theranostic nanomedicine for cancer. Nanomedicine (Lond) 2008, 3:137-140.
30. Mok H., Park J.W., Park T.G. Enhanced intracellular delivery of quantum dot and adenovirus nanoparticles triggered by acidic pH via surface charge reversal. Bioconjug Chem 2008, 19:797-801.
31. Saggar J.K., Yu M., Tan Q., Tannock I.F. The tumor microenvironment and strategies to improve drug distribution. Fron Oncol 2013, 3:154.
32. Nie S. Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine (Lond) 2010, 5:523-528.
33. Desai N. Challenges in development of nanoparticle-based therapeutics. AAPS J 2012, 14:282-295.
34. Luo S., Tan X., Qi Q., Guo Q., Ran X., Zhang L., et al. Amultifunctional heptamethine near-infrared dye for cancer theranosis. Biomaterials 2013, 34:2244-2251.
35. Tan X., Luo S., Wang D., Su Y., Cheng T., Shi C. ANIR heptamethine dye with intrinsic cancer targeting, imaging and photosensitizing properties. Biomaterials 2012, 33:2230-2239.
36. Lim C.K., Shin J., Lee Y.D., Kim J., Oh K.S., Yuk S.H., et al. Phthalocyanine-aggregated polymeric nanoparticles as tumor-homing near-infrared absorbers for photothermal therapy of cancer. Theranostics 2012, 2:871-879.
37. Zhang E., Luo S., Tan X., Shi C. Mechanistic study of IR-780 dye as a potential tumor targeting and drug delivery agent. Biomaterials 2014, 35:771-778.